Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Matinas BioPharma Hldgs Q2 EPS $(0.03), Inline

Matinas BioPharma Hldgs (AMEX:MTNB) reported quarterly losses of $(0.03) per share which met the analyst consensus estimate. This is a 50 percent decrease over losses of $(0.02) per share from the same period last year.
byBenzinga Newsdesk
August 11, 2022
1 minute read
Total
0
Shares
0
0
0
0
0
0

Matinas BioPharma Hldgs (AMEX:MTNB) reported quarterly losses of $(0.03) per share which met the analyst consensus estimate. This is a 50 percent decrease over losses of $(0.02) per share from the same period last year.

 
Total
0
Shares
Share 0
Tweet 0
Share 0
Share 0
Share 0
Share 0
Related Posts
Read More

MediciNova Reached Agreement to Participate in Grant-Funded Clinical Trial to Evaluate MN-166 (ibudilast) for the Treatment of Long COVID

By Charles Gross
Yesterday, 6:34 AM
MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ: MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that it plans to participate in RECLAIM (Recovering from COVID-19 Lingering Symptoms Adaptive Integrative Medicine Trial), a grant-funded, multi-

MNOV